684283-02-1Relevant academic research and scientific papers
Synthesis and Characterization of Some α,β-Didehydroamino Acid Derivatives
Su, Guifa,Pan, Chengxue,Wang, Hengshan,Zeng, Longmei
, p. 665 - 671 (2004)
A mild Horner-Wadsworth-Emmons reaction is described. Treatment 4-substituted cyclohexanones with trimethyl 1-(N-benzyloxycarbonyl) phosphonoacetate afforded the corresponding α,β-didehydroamino acid derivatives.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 56; 57, (2014/05/24)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 130-131, (2012/02/15)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 102-103, (2012/03/09)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 56, (2012/12/13)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 131-132, (2011/06/16)
The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 126-127, (2011/07/07)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
AZAINDOLE INHIBITORS OF IAP
-
Page/Page column 37, (2010/04/03)
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: I wherein X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and R9 are as described herein.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 184, (2010/12/26)
This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 140-141, (2010/12/26)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
